{"nctId":"NCT03891758","briefTitle":"Confirmatory Study of BK1310 in Healthy Infants","startDateStruct":{"date":"2019-04-01","type":"ACTUAL"},"conditions":["Tetanus","Diphtheria","Pertussis","Poliomyelitis","Bacterial Meningitis"],"count":267,"armGroups":[{"label":"BK1310","type":"EXPERIMENTAL","interventionNames":["Biological: DPT-IPV-Hib"]},{"label":"ActHIB® and Tetrabik","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hib vaccine","Biological: DPT-IPV"]}],"interventions":[{"name":"DPT-IPV-Hib","otherNames":["BK1310"]},{"name":"Hib vaccine","otherNames":["ActHIB®"]},{"name":"DPT-IPV","otherNames":["Tetrabik"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants aged ≥2 and \\<43 months at the first vaccination of the study drug (recommended: ≥2 and \\<7 months)\n* Written informed consent is obtained from a legal guardian (parent)\n\nExclusion Criteria:\n\n* Possibility of anaphylaxis due to food or pharmaceuticals\n* With experience of Hib infection, diphtheria, pertussis, tetanus or acute poliomyelitis\n* With experience of Hib, diphteria, pertussis, tetanus or polio vaccination.\n* Participated in other studies within 12 weeks before obtaining consent\n* Considered to be not eligible by the principal investigators (sub-investigators) of the enrollment\n\nAdditional screening criteria check may apply for qualification.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"42 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Anti-PRP","description":"Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \\>=0.1 IU/mL, Anti-PT antibody concentrations: \\>=10.0 EU/mL, Anti-FHA antibody concentrations: \\>=10.0 EU/mL, Anti-tetanus antibody concentrations: \\>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \\>=8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"88.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer of Anti-PRP Antibody","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.688","spread":null},{"groupId":"OG001","value":"6.698","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 1 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRP Antibody Prevalence Rate With 0.15 μg/mL or Higher, Defined as the Percentage of Participants With the Anti-PRP Antibody","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer of Anti-PRP Antibody","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.545","spread":null},{"groupId":"OG001","value":"34.246","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Diphtheria Toxin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.841","spread":null},{"groupId":"OG001","value":"1.283","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.30","spread":null},{"groupId":"OG001","value":"200.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.48","spread":null},{"groupId":"OG001","value":"85.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Tetanus Toxin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.473","spread":null},{"groupId":"OG001","value":"0.158","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Polio Virus","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"684.95","spread":null},{"groupId":"OG001","value":"663.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2026.44","spread":null},{"groupId":"OG001","value":"1767.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1729.00","spread":null},{"groupId":"OG001","value":"2075.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Prevalence Rate Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants With the Antibody Against Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus","description":"Antibody prevalence rate is defined as the percentage of participants whose criteria of each antibody titer: Anti-diphtheria antibody concentrations: \\>=0.1 IU/mL, Anti-PT antibody concentrations: \\>=10.0 EU/mL, Anti-FHA antibody concentrations: \\>=10.0 EU/mL, Anti-tetanus antibody concentrations: \\>=0.01 IU/mL, Anti-poliovirus serotype 1,2 and 3 antibody titers (fold) \\>=8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Diphtheria Toxin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.766","spread":null},{"groupId":"OG001","value":"8.961","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Pertussis","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"209.05","spread":null},{"groupId":"OG001","value":"279.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144.73","spread":null},{"groupId":"OG001","value":"221.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Antibody Titer Against Tetanus Toxin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.904","spread":null},{"groupId":"OG001","value":"0.598","spread":null}]}]}]},{"type":"SECONDARY","title":"Fold Change in Geometric Mean Antibody Titer Against Polio Virus","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2524.05","spread":null},{"groupId":"OG001","value":"2662.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8821.88","spread":null},{"groupId":"OG001","value":"7512.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6439.23","spread":null},{"groupId":"OG001","value":"7355.96","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":133},"commonTop":["Injection site erythema","Pyrexia","Injection site induration","Injection site swelling","Irritability postvaccinal"]}}}